title: Outcome of adult patients with acute myeloid leukemia who failed to achieve complete remission after one course of induction chemotherapy: a report from the BGMT Study Group.
abstract: Between 50 and 75% of adult patients with de novo acute myeloid leukemia achieve complete remission (CR) but 25 to 40% of them require more than one course of induction chemotherapy to achieve CR. In order to investigate the impact of this situation on the overall outcome of patients we conducted a retrospective analysis of 130 patients, resistant to a single induction course from among three consecutive protocols, using the same induction regimen employed by the BGMT study group. This group of patients has a particularly poor prognosis with relapse and survival rates of 70% and 14% respectively at 5 years. For these patients, being in CR after two induction courses appears to be a major prognostic factor for outcome, since the 5-year Kaplan-Meier survival probability is significantly better (29%, range 17-46) than of those patients with resistant disease (5%, range 2-13). However, results are worse than when complete remission is obtained after a single course. Thus, post remission treatment should have a powerful anti-leukemic effect in preventing relapse. Allogeneic bone marrow transplantation is a preferential strategy in this setting but to be effective this should be performed as early as possible. Furthermore, these results indicate that allogeneic bone marrow transplantation from an alternative donor should be considered in the absence of HLA identical sibling.
authors.affiliation: Hôpital Caremeau, CHU Nîmes, France.
authors.forename: E
authors.initials: E
authors.lastname: Jourdan
authors.forename: J
authors.initials: J
authors.lastname: Reiffers
authors.forename: A M
authors.initials: AM
authors.lastname: Stoppa
authors.forename: J J
authors.initials: JJ
authors.lastname: Sotto
authors.forename: M
authors.initials: M
authors.lastname: Attal
authors.forename: R
authors.initials: R
authors.lastname: Bouabdallaha
authors.forename: G
authors.initials: G
authors.lastname: Marit
authors.forename: N
authors.initials: N
authors.lastname: Fégueux
authors.forename: O
authors.initials: O
authors.lastname: Boulat
authors.forename: N
authors.initials: N
authors.lastname: Dastugue
authors.forename: J M
authors.initials: JM
authors.lastname: Boiron
authors.forename: C
authors.initials: C
authors.lastname: Fabères
authors.forename: J A
authors.initials: JA
authors.lastname: Gastaut
authors.forename: D
authors.initials: D
authors.lastname: Maraninchi
authors.forename: D
authors.initials: D
authors.lastname: Blaise
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D016026:Bone Marrow Transplantation / Q000401:mortality; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D014184:Transplantation, Homologous / Q000401:mortality; D016896:Treatment Outcome